Summary
The pharmacokinetics of hydrochlorothiazide (HCT) was investigated in 23 subjects with normal renal function or widely varying degrees of renal failure. The half-life of elimination increased from 6.4 h in subjects with normal renal function to 11.5 h in patients with mild renal impairment (endogenous creatinine clearance between 30 and 90 ml/min), and to 20.7 h in patients with an endogenous creatinine clearance below 30 ml/min. The cumulative urinary excretion and the renal HCT clearance were correspondingly reduced in patients with impaired kidney function. In normal subjects HCT was mainly excreted by tubular secretion, but as renal HCT clearance in patients with renal impairment did not differ significantly from endogenous creatinine clearance, it was concluded that the secretory mechanism is most markedly impaired. In patients with an endogenous creatinine clearance of 30 to 90 ml/min, the dosage of HCT should be reduced to 1/2 and in patients with a endogenous creatinine clearance below 30 ml/min to 1/4 of the normal daily dose to avoid dose dependant side-effects.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anderson KV, Brettell HR, Aikawa JK (1961) 14C-labeled hydrochlorothiazide in human beeings. Arch Intern Med 107: 736–742
Beermann B, Groschinsky-Grind M (1977) Pharmacokinetics of hydrochlorothiazide in man. Eur J Clin Pharmacol 12: 297–303
Beermann B, Groschinsky-Grind M (1978) Antihypertensive effect of various doses of hydrochlorothiazide and its relation to plasma level of the drug. Eur J Clin Pharmacol 13: 195–201
Beermann B, Groschinsky-Grind M (1978) Gastrointestinal absorption of hydrochlorothiazide enhanced by concomitant intake of food. Eur J Clin Pharmacol 13: 125–128
Beermann B, Groschinsky-Grind M (1979) Pharmacokinetics of hydrochlorothiazide in patients with congestive heart failure. Br J Clin Pharmacol 7: 579–583
Beermann B, Groschinsky-Grind M, Lindström B (1977) Biovailability of two hydrochlorothiazide preparations. Eur J Clin Pharmacol 11: 203–205
Beermann B, Groschinsky-Grind M, Rosen A (1976) Absorption, metabolism, and excretion of hydrochlorothiazide. Clin Pharmacol Ther 19: 531–537
Baur G, Kurz H, Trunk H (1977) Alteration of protein binding during storage of human plasma preparations. Anaesthesist 26: 148–150
Cooper MJ, Anders MW, Sinaiko AR, Mirkin BL (1976) Applikation of HPLC to the study of the disposition of hydrochlorothiazide in adults and children. In: Dixon PF (ed) High pressure liquid chromatography in clinical chemistry. Academic Press, London
Dettli L (1977) Elimination kinetics and dosage adjustment of drugs in patients with kidney disease. Fischer, Stuttgart New York
Jordö L, Johnsson G, Lundborg P, Persson BA, Regardh CG, Rönn D (1979) Bioavailability and disposition of metroprolol and hydrochlorothiazide combined in one tablet and of separate doses of hydrochlorothiazide. Br J Clin Pharmacol 7: 563–567
Mirkin BL, Green TP, O'Dea RF (1980) Disposition and pharmacodynamics of diuretics and antihypertensive agents in renal disease. Eur J Clin Pharmacol 18: 109–116
Nakano M, Fujii K, Goto S (1979) Binding of diuretics to human serum albumin and to human serum from healthy adults and patients with renal failure. Chem Pharm Bull 27: 101–108
Schäfer M, Geissler HE, Mutschler E (1977) Fluorimetrische Bestimmung von Hydrochlorothiazid in Körperflüssigkeiten durch direkte Auswertung von Dünnschichtchromatogrammen. J Chromatogr Biomed Applicat 143: 615–623
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Niemeyer, C., Hasenfuß, G., Wais, U. et al. Pharmacokinetics of hydrochlorothiazide in relation to renal function. Eur J Clin Pharmacol 24, 661–665 (1983). https://doi.org/10.1007/BF00542218
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00542218